The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 7, 2020

The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinical trials in the future. In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Treatment Hospitals 52

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 40

Trials Treatment Small Molecule Hospitals 40

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. The full set of results will be published once the complete Phase 1/2a trial data are available.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 17, 2020

More than 100,000 people have signed up to take part in future NHS trials of a coronavirus vaccine – but more volunteers are needed, researchers say. Kate Bingham, who chairs the UK’s vaccine taskforce, said: “These trials are safe, please sign up. And hundreds of thousands of volunteers will be needed.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

SEPTEMBER 3, 2020

Rachel Murray, seven, took part in the trial. Anyone with any of these should isolate and get tested for the virus. In the trial, nearly 1,000 children had their blood tested to see if they had recently caught coronavirus. None of the children in the study was seriously ill or needed to be admitted to hospital.

Virus 52

Virus Trials Hospitals Disease 52

The Pharma Data

NOVEMBER 22, 2020

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. Trials are also being run in the U.S.,

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

OCTOBER 22, 2020

Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. to 1.52).

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

AUGUST 11, 2020

It has not received general approval to treat the virus in the US, but has in several European countries and Japan. The request for approval comes nearly two months after a study from the National Institute of Allergy and Infectious Diseases which showed positive results, with the drug effectively blocking the virus from replicating.

FDA Approval 52

FDA Approval FDA Government Virus 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * About VAT08 and VAT02 The Phase 3 trial, VAT08 is evaluating a 10µg antigen formulation of the SARS-CoV-2 adjuvanted recombinant protein-based vaccine?for

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

JANUARY 21, 2021

Eli Lilly reported yesterday that its monoclonal antibody bamlanivimab (LY-CoV555) significantly lessened the risk of contracting COVID-19 among nursing home residents and staff, according to findings from a phase 3 trial. James Miessler.

Nurses 52

Nurses Research Laboratories Laboratories Virus 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 21, 2020

Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was conducted in Brazil under a U.S. RESEARCH TRIANGLE PARK, N.C.,

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

DECEMBER 3, 2020

These tools, therefore, have the potential to advance population screening and clinical trials.”. The changes help the virus to multiply and eventually destroy the cells. Kidney Disease Leading Risk Factor for COVID-related Hospitalization. Of them, 1,604 were COVID-positive and 354 required hospitalization.

Disease 52

Disease Research Virus Hospitals 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. We continuously strive to stay at least one step ahead of the virus. adult participants from the Phase 1 trial of the two-dose series.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

Trial Also Met the Primary Endpoint in Patients With Low Levels of Eosinophils. In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, the trial met the primary endpoint with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

NOVEMBER 23, 2020

It is an mRNA vaccine that codes for the virus’s spike protein and is encapsulated in a lipid nanoparticle. Once injected, the cells churn out the spike protein, triggering the body’s immune system to recognize the virus. In Phase III trials, it demonstrated 95% efficacy. Type: mRNA. Doses: 2, 28 Days Apart.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

AUGUST 30, 2021

Pulmonary infection with the SARS-CoV2 virus can progress to acute respiratory distress syndrome (ARDS), in which inflammation and neutrophil hyperactivation play a central role. MADRID-COVID is a randomized clinical trial conducted in close collaboration between the CNIC and cardiology, ICU, pulmonology, and biobank services at FJD Hospital.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

The Pharma Data

OCTOBER 27, 2021

. “The main finding in our study is that the equine hyperimmune globulins antibodies developed against the spike protein of the ancestral SARS-CoV-2 had high neutralizing action against the new variants of the virus, such as the gamma strain. The next step of the research is to conduct a phase 1/2 clinical trial in humans.

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. ” COVID-19 was also a major focus of this year’s meeting. . Also, much of the microthrombi occurring in these patients appears to be a direct result of the infection.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

JANUARY 14, 2021

Australian researchers have found stable levels of virus-specific immune memory cells in the blood of COVID-19 patients as much as eight months post-infection, according to findings published in the journal Science Immunology in December. “There isn’t a concern on that front.” © 2021 HealthDay.

Vaccine 52

Vaccine Trials Virus Hospitals 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 — Viral load was decreased at day 11 for patients with mild or moderate COVID-19 who received a single intravenous infusion of virus-neutralizing monoclonal antibody versus placebo, according to a study published online Oct. The percentage of patients with a COVID-19-related hospitalization or emergency department visit was 1.6

RNA 52

RNA Virus Hospitals Trials 52

The Pharma Data

SEPTEMBER 29, 2020

He also hears about a trial in the US to test whether prayer can help Covid patients in intensive care. He picked up the virus right at the start of the pandemic and had a relentless and gruelling illness followed by a lingering debilitation that has lasted over six months. This is no Mickey Mouse trial either.

Doctors 52

Doctors Trials Virus Government 52

The Pharma Data

AUGUST 24, 2020

The National Medical Products Administration has granted approval to the West China Hospital of Sichuan University in Chengdu to begin a clinical trial. Although there is speculation that Russia may also be testing vaccines outside of clinical trials, this is the first direct confirmation of it by any country.

Vaccine 40

Vaccine Clinical Trials Packaging Regulations 40

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. These studies narrowed the list to 73 human proteins that the virus depends on to replicate. That’s the strategy employed by remdesivir , the only antiviral drug currently authorized by the U.S.

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. COVID-19 Research.

Virus 40

Virus Treatment Science Trials 40

The Pharma Data

DECEMBER 14, 2020

AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S. The Phase I trial is a randomized, double-blind, placebo-controlled study that is meant to evaluate the safety, pharmacokinetics and pharmacodynamics of single ascending doses of ABBV-47D11.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

SEPTEMBER 5, 2021

“This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

DECEMBER 23, 2020

While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s On December 3, the PureTech initiated a global, Phase II trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae. The trial is ongoing in the U.S. PureTech Health Plc.,

Clinical Trials 52

Clinical Trials FDA Small Molecule Trials 52

The Pharma Data

AUGUST 20, 2020

What information has been released about how kits were assessed shows most were tested on small numbers of patients only – just a few dozen, all of whom had been admitted to hospital. “For drug licensing the onus is on the companies to go through clinical trials. “There have been a number of arrests. Source link.

Clinical Trials 52

Clinical Trials Regulations Doctors Government 52

The Pharma Data

SEPTEMBER 2, 2020

Although cases are now at a relatively low level, the UK’s chief medical adviser Prof Chris Whitty has said he expects containing the virus to be more difficult as we go into winter. There will also be a trial, in Salford, of the benefits of repeatedly testing a population. Postcode lottery.

Government 52

Government Virus Laboratories Trials 52

The Pharma Data

JANUARY 15, 2021

. “People with all kinds of cardiovascular risk factors and disease should definitely get vaccinated to protect themselves and their families from COVID-19,” said Dr. Mitchell Elkind, a professor of neurology and epidemiology at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center in New York City.

Vaccine 52

Vaccine Virus Immune Response Disease 52